Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 7.44%.

  • Arcutis Biotherapeutics' EBITDA Margin rose 9840.00% to 7.44% in Q3 2025 from the same period last year, while for Sep 2025 it was -14.13%, marking a year-over-year increase of 12632.00%. This contributed to the annual value of -71.26% for FY2024, which is 36670.00% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' EBITDA Margin is 7.44%, which was up 138.43% from -19.36% recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' EBITDA Margin registered a high of 3,541.29% during Q1 2022, and its lowest value of -14,903.86% during Q3 2022.
  • Moreover, its 3-year median value for EBITDA Margin was -90.96% (2024), whereas its average is -477.99%.
  • Over the last 5 years, Arcutis Biotherapeutics' EBITDA Margin had its largest YoY gain of 1,475,501bps in 2023, and its largest YoY loss of 639,739bps in 2023.
  • Arcutis Biotherapeutics' EBITDA Margin (Quarterly) stood at -2,415.03% in 2022, then surged by 192,637bps to -488.66% in 2023, then soared by 47,278bps to -15.87% in 2024, then skyrocketed by 9,840bps to 7.44% in 2025.
  • Its last three reported values are 7.44% in Q3 2025, -19.36% for Q2 2025, and -38.26% during Q1 2025.